Investment Thesis
Liquidia exhibits exceptional profitability with 46.3% operating margins and 39.8% net margins, coupled with robust free cash flow generation of 50.2M (37.8% FCF margin) and a fortress balance sheet featuring 222.8M in cash and minimal leverage (0.18x D/E). However, the extraordinary 1031% revenue growth requires validation of sustainability, particularly given the significant divergence between revenue growth and 50.9% EPS growth, suggesting potential one-time revenues or substantial dilution.
Strengths
- Exceptional profitability with 46.3% operating margin and 39.8% net margin indicating strong product pricing power and operational efficiency
- Fortress balance sheet with 222.8M cash, 0.18x debt-to-equity ratio, and 2.22x current ratio providing substantial financial flexibility and runway
- Strong free cash flow generation of 50.2M with 37.8% FCF margin demonstrating ability to fund operations and growth organically
- Solid liquidity metrics and interest coverage of 7.6x with manageable 19.9M long-term debt load
- Positive returns with 48.7% ROE and 13.2% ROA reflecting efficient capital deployment
Risks
- Unsustainable revenue growth of 1031% YoY likely from product launch/acquisition requiring validation of repeatability and underlying drivers
- Critical disconnect between 1031% revenue growth and 50.9% EPS growth indicating significant share dilution, one-time items, or unusual revenue recognition
- Gross margin marked as N/A suggesting data gaps or unusual revenue structure; pharmaceutical product margins are material to sustainability assessment
- Pharmaceutical sector inherent risks including regulatory approval uncertainty, clinical trial failures, and patent/exclusivity cliff risk not reflected in current financials
- High insider activity (30 Form 4 filings in 90 days) lacks directional context on whether insiders are buying or selling
Key Metrics to Watch
- Sequential revenue trends in next 2-3 quarters to confirm sustainability of growth trajectory beyond the 1031% expansion
- Gross margin realization and product-level profitability breakdown as fundamental to long-term margin sustainability
- Operating cash flow stability and free cash flow conversion rates to validate quality of earnings
- Share dilution trend and fully diluted share count changes explaining EPS growth divergence from revenue growth
- Pipeline advancement metrics and clinical trial status for product candidates driving pharmaceutical revenue base
Financial Metrics
Revenue
132.9M
Net Income
52.9M
EPS (Diluted)
$0.52
Free Cash Flow
50.2M
Total Assets
401.5M
Cash
222.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
46.3%
Net Margin
39.8%
ROE
48.7%
ROA
13.2%
FCF Margin
37.8%
Balance Sheet & Liquidity
Current Ratio
2.22x
Quick Ratio
2.03x
Debt/Equity
0.18x
Debt/Assets
73.0%
Interest Coverage
7.57x
Long-term Debt
19.9M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-13T08:48:57.773079 |
Data as of: 2026-03-31 |
Powered by Claude AI